ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.04
+0.17 (1.92%)
Mar 4, 2026, 4:00 PM EST - Market closed
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 35, with a low estimate of 30 and a high estimate of 40. The average target predicts an increase of 287.17% from the current stock price of 9.04.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 4, 2025.
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +342.48% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +231.86% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +209.73% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +198.67% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +231.86% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
83.35M
from 89.15M
Decreased by -6.50%
Revenue Next Year
183.35M
from 83.35M
Increased by 119.97%
EPS This Year
-1.80
from 0.08
EPS Next Year
-1.35
from -1.80
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 90.5M | 238.0M | ||||
| Avg | 83.4M | 183.4M | ||||
| Low | 76.4M | 148.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.5% | 185.5% | ||||
| Avg | -6.5% | 120.0% | ||||
| Low | -14.3% | 77.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.64 | -0.97 | ||||
| Avg | -1.80 | -1.35 | ||||
| Low | -1.85 | -2.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.